Tom MacDonald is Professor of Clinical Pharmacology & Pharmacoepidemiology in the Medicines Monitoring Unit, Medical School, University of Dundee and Honorary Consultant Physician at Ninewells Hospital and Medical School, Dundee His research interests include hypertension, cardiovascular disease, pharmacoepidemiology and drug safety.
He is currently the Director of Tayside Medicines Monitoring Unit (MEMO) and the Hypertension Research Centre. He is also an elected member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and is the research director of the Regional Cardiovascular Risk Clinic (a European Society of Hypertension designated centre of excellence). He is currently the principal investigator of two large, multi-national, multi-centre streamlined safety studies; the Standard care versus Celecoxib Outcomes Trial (SCOT) and the Febuxostat versus Allopurinol Safety Trial) FAST. He is the Principal Investigator on the TIME study and also on the executive committee for the ALL-HEART and PATHWAY I, 2 and 3 studies.
He is Past President of the British Hypertension Society, the International Society of Pharmacoepidemiology and the Pharmacovigilance Committee on Safety of Medicine.
Professor MacDonald has published extensively on drug safety especially the safety of non steroidal anti-inflammatory drugs (NSAIDs). He has also published many studies of hypertension and other cardiovascular risk factors and cardiovascular disorders.
BSc (Honours), First Class, Pharmacology, University of Aberdeen
MD with Commendation. Thesis Title: The peripheral dopaminergic system in health and disease
Fellow of the Royal College of Physicians of Edinburgh (FRCPE)
JCHMT Accreditation: General Medicine and Clinical Pharmacology
Certificate in Health Economics, Aberdeen University
Fellow of the Royal College of Physicians of London (FRCP)
Doctor of Medicine Honoris Causa, University of Medicine & Pharmacy, Cluj Napoca, Romania
Fellow of the European Society of Cardiology (FESC)
European Society of Hypertension Clinical Hypertension Specialist Diploma
Fellow of the Royal College of Physicians & Surgeons of Glasgow (FRCPSG)
Foundation Fellow of the International Society of Pharmacoepidemiology (FISPE)
Fellow of the British Pharmacological Society (FBPharmacolS)
£25,876,664 The Standard care versus Celecoxib Outcome Trial (SCOT). Pfizer Inc.
£1,894,451 British Heart Foundation Program Grant with British Hypertension Society to study: Prevention And Treatment of resistant Hypertension With Algorithm-based Therapy (PATHWAY) with British Hypertension Society Collaborative Research Working Party.
£90,000 Chest Heart & Stroke Scotland. Does Vitamin D reduce blood pressure and LV mass in resistant hypertensive patients with Vitamin D insufficiency? With AD Struthers, M Witham & G Houston.
£45,000 To study the relationship between FEV1 and patient reported health outcomes in COPD patients. Boehringer Ingelheim.
£323,958 British Heart Foundation. The potential to improve primary prevention by using BNP as an indicator of silent pancardiac target organ damage: the 5P study. (With AD Struthers, CCLang and G Houston).
£24,712,512 The Febuxostat versus Allopurinol Safety Trial (FAST). IPSEN/Menarini Pharmaceuticals.
£9850 Impact of implementation of eGFR reporting on NSAIDs prescribing and patient outcomes. TENOVUS Scotland.
£49,727 Acid suppression medications and bacterial gastroenteritis: a population based cohort study. Chief Scientists Office CZG/2/540
Past President of British Hypertension Society
Trustee; Scottish Heart Arterial Risk Prevention (SHARP).
Steering committee: HEAT trial
Chief Investigator SCOT study
Principal Investigator & executive British Hypertension Society PATHWAY study.
Chief Investigator FAST study
Chief Investigator TIME study